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Hemostasis requires the combined action of blood platelets
and vascular and plasmatic factors, with vonWillebrand factor
(VWF) having a key role. In blood, VWF circulates as a large
glycoprotein (GP) consisting of multimers of heterogeneous
sizes. At high-shear flow conditions, VWF mediates platelet
adhesion via the glycoprotein Ib (GPIb)-V-IX complex, in
particular by depositing to collagen fibres, at which it avidly
binds. Collagen-bound VWF thus plays a critical role in platelet
tethering, translocation, and stable adhesion at arterial flow
conditions above a critical shear rate of 500 to 1,000 s1.1,2
VWF binds to collagen types I and III via its A3
domain, whereas binding to type VI collagen has been attrib-
uted to VWF A1 domain.3–5 In addition, VWF is implicated in
platelet GPIb-dependent procoagulant activity and fibrin for-






► von Willebrand factor
triplets
► platelet adhesion
Abstract Multimeric glycoprotein von Willebrand factor (VWF) exhibits a unique triplet structure
of individual oligomers, resulting from ADAMTS-13 (a disintegrin andmetalloproteinase
with thrombospondin type 1motifs 13) cleavage. The faster and slowermigrating triplet
bands of a given VWF multimer have one shorter or longer N-terminal peptide
sequence, respectively. Within this peptide sequence, the A1 domain regulates
interaction of VWF with platelet glycoprotein (GP)Ib. Therefore, platelet-adhesive
properties of two VWF preparations with similar multimeric distribution but different
triplet composition were investigated for differential functional activities. Preparation A
was enriched in intermediate triplet bands, whereas preparation B predominantly
contained larger triplet bands. Binding studies revealed that preparation A displayed
a reduced affinity for recombinant GPIb but an unchanged affinity for collagen type III
when compared to preparation B. Under high-shear flow conditions, preparation A was
less active in recruiting platelets to collagen type III. Furthermore, when added to blood
from patients with von Willebrand disease (VWD), defective thrombus formation was
less restored. Thus, VWF forms lacking larger-size triplet bands appear to have a
decreased potential to recruit platelets to collagen-bound VWF under arterial flow
conditions. By implication, changes in triplet band distribution observed in patients with
VWD may result in altered platelet adhesion at high-shear flow.
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It is well established that large VWF multimers, which are
secreted from endothelial cells, are cleaved into smaller forms
by the metalloproteinase ADAMTS-13 (a disintegrin and
metalloproteinase with thrombospondin type 1 motifs 13).
This protease cleaves the Y1605-M1606 peptidyl bond within
the A2 domains of VWF multimers, thus generating smaller
size multimers.8 Because of asymmetric cleavage in the VWF
A2 domain, ADAMTS-13 degradation results in larger- and
smaller-size monomeric forms of 176 kDa (C-terminal pep-
tide sequence) and 140 kDa (N-terminal peptide sequence),
respectively (►Fig. 1A). On agarose gels, these represent the
two satellite bands flanking the major band of all VWF
multimers,9,10 forming a so-called VWF triplet. The slower
and faster migrating triplet bands thus either contain or lack
one 140 kDa N-terminal peptide sequence compared to the
intermediate VWF triplet band, respectively.11 The variable
part of individual VWF triplets resides in the N-terminal
protein part comprising the A1 domain, which contains
binding sites for heparin, coagulation factor VIII, and GPIb
and, hence, is highly relevant to VWF function.
Because theproperties of individual VWF triplet bands have
not been investigated so far, we aimed to separate normal
plasma-derived VWF into subfractions with a similar multi-
meric composition but different triplet band patterns. There-
fore, we made use of the property that the longer-chain,
slower-migrating triplet bands of VWF multimers containing
one additional N-terminal 140 kDa peptide sequence more
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Fig. 1 Domain structure of VWF and flowchart to obtain preparations with different VWF triplet distribution. (A) VWF domains indicating binding
sites for heparin and GPIb in the A1 domain. The propeptide of AA 23-763 after cleavage of the prepropeptide is depicted below the domain
structure as well as the mature VWF protein starting with AA 764-2813 (numbering according to the preproprotein). Glycosylation is indicated
as squares (N-linked glycans) and circles (O-linked glycans). ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type
1 motifs 13) cleavage site in the A2 domain is indicated as well. This cleavage results in a 140 kDa N-terminal fragment comprising the D3-A1
domains and part of the A2 domain with binding sites, for example to GPIb and heparin. Cleavage also results in a larger 176 kDa C-terminal
fragment, comprising part of the A2 domain as well as VWF domains A3D4C1C2C3CK. Information source: P04275, UniProtKB/Swiss-Prot
database. (B) Flowchart to separate plasma-derived VWF into preparations with different triplet composition, but similar multimeric composition.
Application of desalted VWF concentrate (wilate®) on heparin affinity chromatography column results in three fractions, fraction F1 (discarded)
and fractions F2 and F3 with distinct triplet composition. By using size exclusion chromatography, F2 and F3 are resolved in subfractions of
similar molecular weight ranges and, hence, similar multimeric composition, giving preparations A and B, respectively. Desalted whole VWF
concentrate is also subjected to size exclusion chromatography to obtain a control preparation with similar molecular weight ranges to
preparations A and B. GPIb, glycoprotein Ib; VWF, von Willebrand factor.
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separation followed by size exclusion chromatography to
obtain VWF preparations with a similar multimer profile but
distinct pattern of triplet bands, resulting in different affinities
to GPIb and different capabilities to promote GPIb-dependent
platelet adhesion under high-shear flow conditions.
Materials and Methods
Materials
Plasma-derived VWF/factor VIII concentrate wilate® (lot no.
A925A189) used for fractionation was from Octapharma
(Vienna, Austria). VWF levels are given as antigen concen-
trations unless indicated otherwise. SHP was used as refer-
ence (Coagulation Control N, Technoclone, Vienna, Austria).
Collagen type III from human placental villi was obtained
fromBiozol Diagnostica (Eching, Germany). F(ab’)2 fragments
of monoclonal antibody (Ab) 6B4 against the VWF-binding
epitope on GPIbαwas a kind gift of Prof. Dr. H. Deckmyn.13H-
Phe-Pro-Arg chloromethyl ketone (PPACK) came from Cal-
biochem (La Jolla, CA).
Isolation of VWF Preparations with Different Triplet
Composition
Plasma-derived VWF concentrate wilate® was desalted using
a PD-10 column and eluted with 20 mM Tris, pH 7.4 (GE
Healthcare, Uppsala, Sweden). The VWF concentratewas then
fractionated according to triplet structure by fast protein
liquid chromatography (FPLC), employing a 5 mL HiTrap
heparin HP affinity column (GE Healthcare) and stepwise
gradient elution with 190, 230, and 500 mM NaCl in 20 mM
Tris, pH 7.4 (►Fig. 2A). Of the three fractions (F1–3), only F2
and F3, obtained at 230 and 500 mM NaCl elution, respec-
tively, were used for further purification. The other fraction
F1 was enriched in the faster-migrating triplet band but
contained only small VWF multimers with low biologic
activity (►Fig. 2A),14 and was hence discarded.
Each of the fractions F2 and F3 (►Fig. 2A), as well as the
unfractionatedwilate® (original sample ¼ control preparation)
were differentially separated into subfractions by FPLC using a
Sepharose CL–2B size exclusion column. Elutionwas performed
with Tris-buffer, pH 7.4 (20 mM Tris, 0.02% v/v Tween 20). Sub-
fractions from this column for each starting sample (i.e., frac-
tions F2 and F3, and control preparation) were then separately
pooled to yield different VWF preparations with a similar
multimeric distribution. This was done for the control prepara-
tion (exemplary shown in ►Fig. 2B), as well as for fractions F2
and F3 (not shown but similar process to that shown for control
preparation in ►Fig 2B) to give preparations A and B, respec-
tively (see ►Fig 1B). Each separate column fraction pool was
then concentrated using an Amicon Ultra-4 centrifugal filter
device (100K; Millipore, Billarica, MA) at 2,000 g to a VWF:Ag
level of about 30 IU/mL. Fraction analysis for VWF multimer
distribution was by 1.2% agarose gel electrophoresis; and
analysis for VWF triplet composition was by 1.6% agarose gel
electrophoresis, followed by Western blotting.15 Densitometric
analysis of blotswasperformedwithMulti Gauge V3.2 software
(Fujifilm, Düsseldorf, Germany).
VWF preparations were assessed for collagen binding
using a VWF:CB ELISA (enzyme-linked immunosorbent as-
say) (TECHNOZYM vWF:CBA ELISA Kit, Technoclone, Vienna,
Austria). VWF ristocetin cofactor activity (VWF:RCo) was
determined using a BCS XP system (Siemens Healthcare,
Fig. 2 Obtaining VWF preparations with different triplet forms by heparin affinity and size exclusion chromatography. (A) Plasma-derived VWF
concentrate was applied to a heparin affinity column, and eluted step-wise with 190, 230, and 500 mM NaCl (gray line of eluent conductivity).
Protein peaks were collected as fractions 1–3 (F1–3) and subjected to Western blotting (1.6% agarose gels). Note differences in multimeric and
triplet band composition of the fractions. F1 containing mostly small VWF multimers with little biological activity was discarded. F2
predominantly contained the medium to large VWF multimers with only intermediate triplet bands, whereas F3 consisted of more of the
larger VWFmultimers enriched in slower migrating triplet bands. (B) Size exclusion chromatography of unseparated VWF concentrate, resulting in
initial elution of larger VWF multimers. Western blots of 1.2% agarose gels illustrate the multimeric sizes of individual fractions, and pooling of
fractions to obtain the control VWF preparation. Note that preparations A and B were obtained using the same size exclusion chromatography as
shown for the control in (B) but starting from fractions F2 and F3, respectively (not shown in this figure). VWF, von Willebrand factor.
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Eschborn, Germany); all values were calibrated against stan-
dard human plasma (SHP).
ELISA Assays
Antigen concentrations of VWF were determined with a
sandwich ELISA with polyclonal anti-human VWF antibody
(Ab) (A0082, Dako,Hamburg, Germany) for capturing, followed
by staining with horseradish peroxidase (HRP)-conjugated
anti-human VWF Ab (P0226, Dako). Sigma Fast OPD tablets
were used as chromogenic substrate (order no. P9187; Sigma-
Aldrich, Schwerte, Germany), color development was termi-
natedwith 1 MHCl, and absorbancewasmeasured at 492 nm.
Binding of VWF fractions to platelet-derived GPIbwas deter-
mined with an immunoassay employing recombinant, FLAG-
tagged GPIbα fragment with two gain-of-function mutations
(G233V and M239V), enabling VWF binding in the absence of
ristocetin.16–18 The rGPIbα fragment was immobilized via its
FLAG tag in 96-well plates precoatedwith anti-FLAG Ab (F3165,
Sigma-Aldrich). Bound VWF was measured using a polyclonal
anti-human VWF Ab and an HRP-conjugated secondary Ab
(A0082 and P0226, Dako) in combination with TMB substrate
solution (T0565, SIGMAFASTOPDperoxidase substrate [P9187],
Sigma Aldrich). The coloring reaction was terminated with
0.5 M H2SO4, and absorbance was read at 450 nm.
Surface Plasmon Resonance
Binding of VWF preparations to collagen type III was deter-
mined by surface plasmon resonance (SPR) using a Biacore
instrument (GE Healthcare), CM5 chips, and amine coupling
chemistry, basicallyas described.19 In brief, collagen type IIIwas
immobilized on the chip surface at an amount of 800 to 1,000
response units (RU). VWF samples were injected at increasing
concentrations (0.2, 0.4, 1.3, and 4 IU/mL) in HBS-EP running
buffer (3.4 mMEDTA, 10 mMHEPES, 150 mMNaCl, 0.005% v/v
Tween 20; pH 7.4) at a flow rate of 20 µL/min. A chip with
immobilized polyclonal rabbit anti-human collagen I-VAb (PC-
169, Kamiya Biomedical, Seattle, WA) served as reference for
unspecific binding. Chips were regenerated after each run.20
For determination of rGPIb binding kinetics by SPR, puri-
fied gain-of-function rGPIbα fragment carrying a His-tag was
immobilized onto NTA-chips (GE Healthcare) at 1,000 RU.
Samples of VWFwere injected at increasing concentrations of
0.3, 0.9, 2.8, and 8.4 IU/mL. Analysis of all SPR binding curves
was done with BiaEvaluation software (GE Healthcare), as-
suming Langmuir 1:1 binding kinetics and a molecular
weight of the VWF monomer of 270 kDa.
Platelet Adhesion and Thrombus Formation under
Flow
Leukocyte-depleted platelet concentrates collected by
aphaeresis and red cell concentrates were obtained from
Haema (Berlin, Germany). These concentrates were used to
prepare washed platelets and red cells, respectively. Shear-
and VWF-dependent platelet adhesion to collagen type III
using reconstituted blood was performed, as described else-
where.21 Briefly, 2.5  108 platelets/mL were labelledwith 5-
chloromethylfluorescein diacetate (CMFDA, Invitrogen,
Karlsruhe, Germany), and reconstituted with washed red
cells (hematocrit of 40%) and VWF preparations (1 IU/mL).
Viscosity of the reconstituted blood samples was measured
with an AMVn falling sphere viscometer (Anton Paar, Ostfil-
dern, Germany) to ensure a dynamic viscosity of approxi-
mately 3 mPa·s. Samples were perfused at a shear rate of
1,700 s1 through a flow chamber coated with collagen
type III (µ-slide VI, Ibidi, Munich, Germany). Platelet adhesion
was monitored in real time for up to 8 minutes. After
perfusion and fixation, 24 randomly chosen images in the
centre of the flow channel were recorded and analyzed using
AxioVision 4.6 software (Carl Zeiss, Göttingen, Germany).
The VWF preparations were also tested in whole-blood
perfusion assays, using aminiaturized parallel-plateflowcham-
ber and equipment, as described before.22,23 Chamber surfaces
were coated with collagen type III (0.1 mg/mL), and blocked
with HEPES buffer, pH 7.45 plus 1% BSA. Experiments were
carried out with blood from healthy controls and from two
patients with VWD. A patient with type 1 VWD had a VWF:RCo
activity of 29%. A patient with type 2A VWD had a VWF:RCo
activity of < 10%, a VWF antigen level of 25 to 35%, and a factor
VIII level of 30%; multimer analysis revealed that the highest
multimers were lacking, which is compatible with type 2A.
Blood was drawn into PPACK anticoagulant, as described
previously.24 This direct thrombin active-site inhibitor
achieves complete anticoagulation while maintaining physi-
ologic concentrations of free Mg2þ and Ca2þ ions. Blood
samples were spiked with vehicle or VWF preparations at
final concentrations of 2 IU/mL. The blood was then perfused
through the flow chamber at a shear rate of 1,700 s1 for
4 minutes. Four to five randomly chosen phase-contrast
images were captured with a digital CCD camera at the end
of perfusion. Imageswere analyzed as described earlier. Blood
donors had given full informed consent, and not taken
medication interfering with platelet function for at least
2 weeks.
Statistical Analyses
Significance of datawas analyzedwithGraphPad Prismversion
5.01 (GraphPad Software, San Diego, CA). Normal distribution
was confirmed using the Kolmogorov-Smirnov normality test.
Differences between grouped data were compared with an
unpaired Student t test. Data from gels with VWF multimers
and SPR analyses were compared by two-way analysis of
variance, using Bonferroni posttesting to compare replicates.
Results
Separation of plasma-derived VWF by heparin affinity chro-
matography (►Fig. 1) resulted in two fractions (F2 and F3)
with marked differences in triplet structure, but also to some
extent in multimeric composition (►Fig. 2A). Each of the
fractions, as well as the original VWF preparation (used as a
control) was further separated by size exclusion chromatog-
raphy, and subfractions were pooled to obtain preparations
with equal multimeric distribution (process shown
in ►Fig. 2B exemplary for the control).
The resulting fractionated VWF pools, preparation A and B,
as well as the (unfractionated) control preparation, were
Seminars in Thrombosis & Hemostasis Vol. 39 No. 3/2013






























characterized by electrophoresis on low- and high-resolution
agarose gels and Western blotting (►Fig. 3A). Densitometric
analysis of blots showed that, as aimed for, preparations A and
B were similar in multimer composition (2 to 13mer), as was
the control preparation (►Fig. 3B, p > 0.05). A significant
difference in the preparations was only seen in the 1-mer
composition, but this was not expected to influence subse-
quent findings. Importantly, the various preparations dis-
played marked and significant differences with regard to
triplet band composition (►Fig. 3C). Preparation B was greatly
enriched in the slowermigrating triplet bands of essentially all
multimers at the expense of intermediate triplet bands; in
comparison, preparation A was greatly reduced in the slower
migrating triplet bands and contained larger proportions of
intermediate triplet bands (p < 0.001). Accordingly, the two-
column separation had resulted in two VWF fractions with
prominent differences in presence of larger-size triplet bands,
but with similar multimeric composition.
The original VWF concentrate as well as the various
preparations were concentrated to obtain solutions with
the same VWF antigen concentrations, and further character-
ized using conventional VWF assays, namely VWF:CB and
VWF:RCo. VWF:CB to VWF:Ag ratios were: 1.21  0.10
(original sample), 0.91  0.02 (control), 0.81  0.02 (Prep.
A), and 0.78  0.01 (Prep. B); VWF:RCo to VWF:Ag ratios
were 0.41  0.04 (original sample), 0.37  0.01 (control),
0.37  0.01 (Prep. A), and 0.42  0.01 (Prep. B). Hence, in
comparison to the original VWD concentrate, the column-
separated preparations were slightly reduced in collagen
binding and ristocetin cofactor activity, most likely due to
partial retaining of the highest multimers on the heparin
column (see following). Notably, preparation B had higher
VWF:RCo, but similar VWF:CB compared to preparation A.
Using SPR, we analyzed binding properties of the three
preparations to surface-immobilized collagen type III.
Preparations A and B gave similar binding curves, when applied
at increasing concentrations of 0.2 to 4 IU/mL (►Fig. 4A).
Determination of the affinity constants, assuming conventional
Langmuir kinetics, resulted in similar dissociation equilibrium
constant (KD) values of 15 to 25 nM (►Fig. 4B), indicating no
significant difference in binding affinity of the two preparations
to collagen type III (p ¼ 0.95). Both preparations displayed a
tendency to diminished collagen binding in comparison to the
unseparated control preparation.
Using a newly established method, a gain-of-function
rGPIb fragment was immobilized to Biacore chips to investi-
gate binding of the preparations to the platelet GPIb receptor.
Binding curves were generated after injection of increasing
concentrations of the VWF preparations (►Fig. 5A). Striking-
ly, the binding affinity of preparation A in this case was
significantly lower than of preparation B (►Fig. 5B,
p ¼ 0.0014). This lower affinity was due to a slower associa-
tion rate in combination with a faster dissociation rate.
Furthermore, at equal antigen concentrations, the maximal
binding was on average 30% lower for preparation A than for
preparation B, likely as a consequence of the lower affinity.
To confirm these differences in binding to GPIb, we also
used an ELISA setup, where the same gain-of-function rGPIb
fragment was immobilized on well plates. In this immuno-
based assay, preparation A again showed a lower binding to
GPIb than preparation B (►Fig. 5C, p < 0.0001), such in
agreement with the results obtained by SPR.
For functional analyses, we then investigated the ability of
the VWF preparations to support GPIb-dependent platelet
adhesion to type III collagen at high shear flow conditions. In
Fig. 3 Triplet and multimer composition of fractionated VWF
preparations. Comparison of control preparation with normal triplet
structure (VWF concentrate subjected to size exclusion chromatog-
raphy), and preparations A and B (separated by heparin affinity
chromatography and then size exclusion chromatography) analysed by
agarose gel electrophoresis and Western blotting. (A) Representative
Western blots. Left: low-resolution 1.2% agarose gels, showing mul-
timer sizes from 1mer to 13mer (*1mer band plus dye front). Right:
high-resolution 1.6% agarose gels, showing triplet composition of
multimers with faster, intermediate and slower migrating triplet bands
(arrowheads). Note that preparations A and B, and the control
preparation were similar in multimer composition (2–13mer).
(B) Relative distribution of VWF 1–13mer multimers of control
preparation and preparations A and B. (C) Proportions of each of the
three triplet bands in control preparation and preparations A and B.
Mean  SEM (n ¼ 4). Note here the difference in triplet bands:
Preparation A was enriched in intermediate triplet bands, while
preparation B predominantly contained larger triplet bands. SEM,
standard error of mean; VWF, von Willebrand factor.
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the first set of experiments, reconstituted blood samples con-
taining platelets (CMFDA-labelled) and red blood cells were
supplemented with the control VWF preparation or with
preparation A or B at 1 IU VWF/mL. After perfusion over
collagen, the coverage of adhered platelets was determined
by fluorescence microscopy. In this flow assay, preparation A
wassignificantly less active in supporting platelet adhesion than
preparation B (►Fig. 6, p < 0.0001). To demonstrate the impor-
tance of VWF-GPIb interaction, similar flow experiments were
performed in the presence of 6B4 mAb, directed against the
VWF binding site of GPIb.25 As indicated in ►Fig. 6B, this
antibody completely annulled the platelet-adhesive effect of
the most active preparation B (►Fig. 6B, p < 0.0001).
In a second range of experiments, we compared the effects
of addition of a recombined F1-3 preparation with that of the
original VWF concentrate. The combination of F1, F2, and F3
gave a multimeric distribution pattern similar to that of the
VWF preparations A/B (Supplementary Fig. S1, online only).
Addition of either preparation (2 IU VWF/mL, final) to the
reconstituted blood resulted in a similar increase in platelet
deposition on collagen as seen with the combination of
preparations A and B (Supplementary Fig. S2, online only).
This indicated that most of the biologic activity of VWF was
retained in the preparations A and B.
In addition, we performed perfusion studies with whole
blood fromVWDpatients containing reduced baseline levels of
VWF. Bloodwas thus obtained from a patient with VWD type 1
(29% VWF:RCo activity) and a patient with VWD type 2A
( < 10% VWF:RCo activity). Samples of blood were spiked
with the control preparation or with preparation A or B. After
4-minute perfusion at 1,700 s1 shear rate, platelet deposition
in thrombi was determined by enhanced contrast video mi-
croscopy. As shown in ►Fig. 7, supplementation of all VWF
preparations (control, A, or B) at 2 IU/mL VWF resulted in a
significant increase in platelet depositionwith both type 1 and
type 2A patient blood (p < 0.05). For the type 1 VWD patient,
no significant differencewas seen between preparations A and
B. However, for the type 2A VWD patient, preparation A was
significantly less effective than preparation B in stimulating
thrombus formation (p ¼ 0.0133). Further control experi-
ments showed that none of the preparationsmodified platelet
deposition when added to blood from subjects with normal
VWF levels (data not shown). Together, these findings suggest
that VWF triplets lacking an additional 140 kDa N-terminal
peptide sequence with the VWFA1 domain containing a GPIb
binding site are decreased in binding affinity to platelet GPIb
and are less active in supporting platelet thrombus formation
on collagen type III under high-shear flow conditions.
Discussion
Distinct cleavage of VWF multimers in the A2 domain by the
metalloproteinase ADAMTS-13 results in VWF forms of vari-



































































Control Prep. A Prep. B
A
B
Fig. 4 Binding of VWF preparations to collagen. Binding kinetics of VWF preparations to collagen type III were established by surface plasmon
resonance measurements. (A) Representative binding curves with increasing concentrations of 0.2, 0.4, 1.3, and 4 IU/mL for control preparation
and for preparations A and B, as indicated. Binding is expressed as RU. (B) Calculated affinity constant values (KD) of the three VWF preparations.
Mean  SEM (n ¼ 6). RU, response units; SEM, standard error of mean; VWF, von Willebrand factor.
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(so-called triplet bands).10–12,26,27 The slower migrating trip-
let bands of VWF multimers thereby contain an additional
140 kDa N-terminal peptide fragment, whereas this N-
terminal part is missing in the faster migrating triplets
when compared to the respective intermediate VWF triplet
bands.11 Importantly, the N-terminal part of VWFmonomers
that is cleaved off by ADAMTS-13 proteolysis comprises the
D1D2D3A1 domains and part of the A2 domain. This part is
known to be involved in the binding of VWF to coagulation
factor VIII, heparin, collagen, and platelet GPIb (reviewed
by28). The literature provides indirect evidence that distinct
triplet bands of the VWF multimers may differ in functional
properties, but so far this has not directly been shown. For
instance, an altered VWF triplet composition is detected in
type 2A or 2B VWD, that is, in forms of VWD that are
characterized by altered VWF binding to platelets, likely as
a consequence of changes in VWF proteolysis.29,30 In other
disease forms, like type 2M VWD, satellite bands can even be
absent, despite the presence of normal or even supra-normal
multimers, which associates with defects in platelet-VWF
interaction.31
For this article, we have functionally characterized two
VWF preparations separated by heparin affinity and size-
exclusion chromatography, which are equal in VWF multi-
meric distributionpatterns butmarkedly differ in triplet band
composition. Binding studies using SPR- and ELISA-based
approaches indicate that preparation A, lacking an extra N-
terminal peptide sequence compared to preparation B, shows
a significantly lower affinity for GPIb. In contrast, both
preparations display an equal binding affinity for type III
collagen. The relatively decreased function of preparation A is
confirmed by two sets of flow studies, investigating platelet
adhesion and thrombus formation due to interaction of the
GPIb-V-IX complex with VWF. High-shear flow experiments
over type III collagen, using either reconstituted blood21 or
whole blood from VWD patients,22 thus show significantly
lower platelet deposition and thrombus formation in the
presence of preparation A than of preparation B. Together,
these finding suggest that the larger size VWF triplet bands,
containing an additional N-terminal peptide sequence, are
more potent in recruiting platelets under arterial flow con-
ditions. However, a limitation of our work is that the heparin
fractionation had resulted in the partial loss of very high VWF
multimers.
The presence or absence of the N-terminal fragment with











































































80 p < 0.0001










20 p < 0.001




Fig. 5 Binding of VWF preparations to recombinant GPIb. Surface plasmon resonance measurements to assess binding of VWF preparations to a
gain-of-function rGPIb fragment. (A) Representative binding curves, expressed as RU at increasing concentrations of 0.3, 0.9, 2.8, and 8.4 IU/mL
for control and preparations A and B. (B) Corresponding KD values. (C) Binding of VWF preparations to rGPIb obtained with ELISA. Data are
expressed as percentage of binding seen in SHP. Mean  SEM (n ¼ 5). ELISA, enzyme-linked immunosorbent assay; GPIb, glycoprotein Ib; RU,
response units; SEM, standard error of mean; SHP, standard human plasma; VWF, von Willebrand factor.
Seminars in Thrombosis & Hemostasis Vol. 39 No. 3/2013






























theoretically negligible for platelet recruitment, taking into
account the overall sum of other GPIb binding sites present in
VWFmultimers. However, given the present results, it is well
feasible that this one additional GPIb binding site, located at
the outer surface of globular multimers, has a considerable
impact on protein function with regard to its sensitivity to
conformational transition in response to fluid dynamic con-
ditions and mechanical forces. Others have also reported on
functional consequences due to the absence of the heparin-
binding site within the A1 domain of VWF, following
ADAMTS-13 cleavage.32,33 The present results suggest that
different functional properties of individual triplet bands are
not only relevant for heparin affinity, but also for GPIb binding
affinity.
Overall, the present results point to a distinct role of the
VWF triplet band composition regarding GPIb-dependent
platelet adhesion to VWF. The larger size, slower migrating
VWF triplet bands appear to be functionally more active in
supporting thrombus formation on collagen type III surfaces.
The implication of these findings is that the altered triplet
band composition regularly observed in type 2 VWD patients
may contribute to an altered VWF-dependent platelet adhe-
sion at high-shear flow.
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Fig. 6 Effect of VWF preparations on shear-dependent platelet adhesion in
reconstituted blood. Flow chamber experiments performed with reconsti-
tuted blood containing CMFDA-labelled platelets (2.5  108/mL) and
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surface at 1700 s1 shear rate. Reconstituted blood samples were supple-
mented with control VWF preparation or preparation A or B (1 IU/mL). The
6B4 mAb (20 µg/mL) against the VWF binding site of GPIb was added, as
indicated. Samples without VWF (baseline) served as negative control.
(A) Representative fluorescence images (bars, 50 µm) after 8-minute
perfusion. (B) Analyzed surface area coverage of fluorescence after 8-minute
perfusion. Mean  SEM (n ¼ 6; 3 different platelet preparations). CMFDA,
5-chloromethylfluorescein diacetate; GPIb, glycoprotein Ib; SEM, standard
error of mean; VWF, von Willebrand factor.
Fig. 7 Effect of VWF preparations on platelet adhesion added to blood
from VWD patients. Whole blood from two VWD patients (type 1 VWD
and 2A VWD with 29% and < 10% VWF:RCo activity, respectively) was
spiked with control VWF preparation or preparation A or B (2 IU/mL),
and then perfused over collagen type III at a shear a rate of 1700 s1.
(A) Representative brightfield images after 4-minute perfusion of
spiked blood from type 2A patient (150  150 µm). (B) Analyzed
surface area coverage of platelets after perfusion of spiked blood from
type 2A VWD patient (left side) and type 1 VWD patient (right side).
Mean  SEM (n ¼ 3 independent experiments).
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